Clinical Trial Update: Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse [Phase 3]

View source ↗

Summary

Phase 3 trial of farletuzumab with carboplatin and taxane in platinum-sensitive ovarian cancer at first relapse was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Farletuzumab (farletuzumab)

Snippet

Sponsor: Morphotek | Conditions: Ovarian Cancer | Phase 3 | Status: TERMINATED | Results posted: 2022-12-30